Mefloquine showed no clear difference in clinical malaria episodes during pregnancy compared with sulfadoxine‐pyrimethamine (high certainty).
Mefloquine leads to lower maternal peripheral parasitaemia at delivery compared with sulfadoxine‐pyrimethamine (high certainty).
Mefloquine showed no clear difference in placental malaria compared with sulfadoxine‐pyrimethamine (low certainty).
Mefloquine probably leads to lower maternal anaemia at delivery compared with sulfadoxine‐pyrimethamine (moderate certainty).
Mefloquine showed no clear difference in low birth weight compared with sulfadoxine‐pyrimethamine (high certainty).
Mefloquine showed no clear difference in stillbirths and abortions compared with sulfadoxine‐pyrimethamine (moderate certainty).
Mefloquine leads to higher AEs: vomiting compared with sulfadoxine‐pyrimethamine (high certainty).
Mefloquine probably leads to higher AEs: dizziness compared with sulfadoxine‐pyrimethamine (moderate certainty).
Mefloquine showed no clear difference in vomiting compared with atovaquone‐proguanil; GRADE not reported.
Mefloquine showed no clear difference in abdominal pain compared with atovaquone‐proguanil; GRADE not reported.
Mefloquine showed no clear difference in diarrhoea compared with atovaquone‐proguanil; GRADE not reported.
Mefloquine showed no clear difference in headache compared with atovaquone‐proguanil; GRADE not reported.
Mefloquine led to higher dizziness compared with atovaquone‐proguanil; GRADE not reported.
Mefloquine showed no clear difference in pruritis compared with atovaquone‐proguanil; GRADE not reported.
Mefloquine showed no clear difference in visual impairment compared with atovaquone‐proguanil; GRADE not reported.
Mefloquine showed no clear difference in mouth ulcers compared with atovaquone‐proguanil; GRADE not reported.
Mefloquine showed no clear difference in clinical malaria compared with doxycycline; GRADE not reported.
Mefloquine showed no clear difference in serious adverse effects compared with doxycycline; GRADE not reported.
Mefloquine showed no clear difference in serious adverse effects compared with atovaquone‐proguanil; GRADE not reported.